R. O’cearbhaill

Society of Gynecologic Oncology Journal Club: Controversial conversations in Gynecologic cancer – The ABCs of ADCs (Antibody drug Conjugates)

L. Chen, U. Matulonis, J. Martin, 2023, Gynecologic oncology reports.

723MO Tisotumab vedotin (TV) + carboplatin (Carbo) in first-line (1L) or + pembrolizumab (Pembro) in previously treated (2L/3L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT-Cx8/GOG-3024/innovaTV 205 study

S. Pignata, M. Mirza, S. Banerjee, 2021, Annals of Oncology.

530P PRIMA/ENGOT-OV26/GOG-3012 study: Updated long-term PFS and safety

B. Monk, M. Mirza, F. Backes, 2022, Annals of Oncology.

177 Efficacy of niraparib by timing of surgery and residual disease: a post-hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study

F. Selle, D. O’Malley, C. Vulsteke, 2021, Ovarian cancer.

Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: A joint statement from GOG foundation and Society of Gynecologic Oncology (SGO).

B. Monk, S. Blank, B. Slomovitz, 2023, Gynecologic oncology.